If there’s any doubt that women’s health is no longer the commercial backwater it once was, tune in to the recent presentation of Hologic Inc. at the February 2008 Merrill Lynch conference. As a result of the 2007 $6.5 billion merger between Cytyc Corp. and Hologic that created the largest pure-play in women’s health, Hologic expects to report sales of $171 billion in 2008. [See Deal] Hologic’s CFO Glenn Muir says the women’s health opportunity in the US is $2.75 billion on an annual basis, and it’s growing at a compounded rate of 16% per year. Looking forward, demographics, the aging of the population, and technological innovations will continue to fuel growth.
New technologies promise to cause one particular category in women’s health to blossom; the treatment of uterine fibroids. Uterine fibroids are a very common hormone-dependent type of benign tumor of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?